ARK Genomic Revolution ETF
ARKG
- $26.85
- 0.02
- 0.07%
ARK Genomic Revolution ETF ARKG Strategy
The investment seeks long-term growth of capital.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
ETFs News & Analysis
etfs
3 things to check before adding another ETF
Portfolio overlap, cost and whether the new potential piece moves you closer to your goals.
etfs
3 different Vanguard ETFs for Aussie share exposure
All 3 ETFs have earned a Bronze Medalist Rating from our analysts.
etfs
Young & Invested: The hidden costs of active ETFs
Why investing in ETFs requires a deep dive into due diligence.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,738.30 | 118.30 | -1.34% |
| CAC 40 | 7,967.93 | 151.09 | -1.86% |
| DAX 40 | 23,180.53 | 409.99 | -1.74% |
| Dow JONES (US) | 46,091.74 | 498.50 | -1.07% |
| FTSE 100 | 9,552.30 | 123.13 | -1.27% |
| HKSE | 25,930.03 | 454.25 | -1.72% |
| NASDAQ | 22,432.85 | 275.23 | -1.21% |
| Nikkei 225 | 48,702.98 | 1,620.93 | -3.22% |
| NZX 50 Index | 13,359.53 | 16.71 | 0.13% |
| S&P 500 | 6,617.32 | 55.09 | -0.83% |
| S&P/ASX 200 | 8,469.10 | 109.70 | -1.28% |
| SSE Composite Index | 3,939.81 | 32.22 | -0.81% |